Muscles naturally become weaker as we grow older, but new scientific research suggests that some of the physiological changes traditionally associated with aging may actually serve a vital protective purpose for muscle cells. An international team of researchers has uncovered why aging muscles undergo a shift toward a different type of muscle fiber, while also identifying a crucial molecule that could point the way toward novel approaches for treating muscle loss and wasting conditions.
Muscle tissue is composed of complex bundles of fibers that serve distinct functions within the human body. Fast-twitch muscle fibers are specialized for generating powerful, rapid movements, yet they tend to fatigue relatively quickly during sustained physical exertion. By contrast, slow-twitch fibers support endurance and prolonged activity. These fibers contain higher concentrations of mitochondria, which are the specialized cellular structures responsible for producing the vast majority of the chemical energy that muscles require to function efficiently.
As people advance in age, overall muscle strength naturally declines, and cellular mitochondria gradually become less efficient at producing energy. Somewhat surprisingly, however, aging muscles also develop a significantly greater proportion of slow-twitch fibers. This occurs even though slow-twitch fibers depend heavily on the very mitochondria that are steadily losing their functional capacity. Researchers have noted remarkably similar cellular alterations in several chronic medical conditions that lead to severe muscle wasting.
This paradox has long puzzled scientists, raising a fundamental question: Why would aging muscles increasingly rely on an energy-producing cellular system that is becoming progressively less effective?
A Crucial Molecule Linked to Muscle Aging
To investigate this deep-seated biological puzzle, an extensive team of scientists focused their attention on cardiolipin, a specialized fat molecule located almost exclusively within the inner membrane of mitochondria. Cardiolipin plays a vital structural role by helping maintain the membrane’s distinctive folded architecture, which is absolutely essential for proper mitochondrial activity and efficient energy production.
When cardiolipin is absent or deficient, mitochondria struggle to generate sufficient energy to support normal cellular operations. Furthermore, they become markedly less capable of producing the essential chemical signals and building blocks that cells require to maintain their health and structural integrity.
Through their investigations, the researchers discovered that cardiolipin levels decline significantly in muscle mitochondria from both mice and humans as they experience normal aging or disease processes. This noticeable drop in cardiolipin was consistently accompanied by structural abnormalities within the mitochondria and a clear loss of normal cellular function.
To determine whether reduced cardiolipin directly drives these degenerative changes rather than simply occurring alongside them as an incidental marker, the research team experimentally lowered cardiolipin levels in young, healthy mice.
The resulting physiological changes closely mirrored what happens during natural biological aging. Muscle fibers shifted away from the fast-twitch variety toward a predominance of slow-twitch fibers, perfectly matching the structural pattern previously observed in older mice and human tissue samples.
Even more strikingly, when the researchers restored cardiolipin concentrations to approximately two-thirds of their normal levels, the intervention began reversing muscle wasting and completely prevented the premature deaths observed in the affected animal models.
Why Aging Muscles Sacrifice Strength for Protection
Further experimental work revealed an unexpected and illuminating explanation for this cellular transformation. Rather than representing a simple breakdown or failure in muscle function, the progressive shift toward slow-twitch fibers appears to be a coordinated, protective response designed to shield the tissue from severe internal stress.
When cardiolipin concentrations drop, damaged mitochondria begin producing much larger quantities of reactive oxygen species, commonly known as ROS. While these highly reactive molecules can inflict serious harm on cellular structures if left unchecked, they also function as vital signaling agents that alert the cell to distress.
The researchers discovered that these elevated levels of ROS help initiate the biological transition from fast-twitch to slow-twitch muscle fibers. When they treated muscle cells lacking sufficient cardiolipin with an antioxidant to chemically neutralize the ROS, the transformation became far less pronounced, demonstrating the signaling role of the molecules.
A regulatory protein known as ERRγ plays a central role in orchestrating this complex response. It directs cells to reorganize their internal mitochondrial networks and alter their muscle fiber characteristics. When the scientists inhibited ERRγ in muscle cells grown in laboratory cultures, the transition between fiber types stopped entirely.
The research team also uncovered the specific mechanisms by which these newly remodeled fibers help defend themselves against ongoing cellular stress.
Mice with insufficient cardiolipin absorbed considerably more glucose directly from their bloodstreams than normal mice did. However, careful tracking using specialized labeled glucose tracers revealed that their muscles were not primarily utilizing this extra sugar to generate mechanical energy.
Instead, muscle cells redirected the abundant glucose toward manufacturing their own internal antioxidants. This metabolic redirection helped protect the cells against the damaging effects of excess reactive oxygen species.
"The fiber switch is not the muscle failing, but the muscle trading power for protection. That’s also why interfering with it can backfire: when we gave the mice antioxidants to mop up the ROS, their muscles fared worse, not better," explains Assistant Professor Fabian Finger, first and co-corresponding author of the study from the University of Copenhagen.
A Potential New Approach to Treating Muscle Wasting
Although these significant findings point toward possible therapeutic strategies for addressing age-related muscle decline, the experiments demonstrating the protective mechanism and the reversal of muscle wasting were conducted primarily in mice. Human muscle samples were utilized in the study specifically to establish that cardiolipin levels do indeed decline with age in people as well.
Nevertheless, researchers already have access to certain pharmacological tools capable of influencing cardiolipin pathways.
The U.S. Food and Drug Administration recently granted accelerated approval to elamipretide, a specialized medication designed to help stabilize cardiolipin, for the treatment of Barth syndrome, a rare inherited genetic disorder. This regulatory milestone suggests that targeting the cardiolipin molecule is clinically feasible, although its specific efficacy against ordinary age-related muscle loss remains to be established in future clinical trials.
Another promising therapeutic target identified by the team is ERRγ, the key regulatory protein responsible for helping muscle tissue adapt to mitochondrial stress.
ERRγ belongs to a broad family of proteins known as nuclear receptors. These receptors are already well-established targets for approximately 10 to 15 percent of all FDA-approved medications derived from small molecules. Furthermore, experimental drugs that activate ERRγ are currently being investigated in preclinical research settings for various other medical applications.
The collective findings suggest that future medical therapies could potentially function either by directly restoring depleted cardiolipin levels or by strategically influencing the protective cellular adaptations controlled by ERRγ.
"What encourages me most is that even a partial recovery of cardiolipin was enough to bring the muscle back. The question now is whether we can increase cardiolipin in aging muscle or target ERRγ to promote healthy adaptations. This is where the therapeutic potential lies," says senior author Zachary Gerhart-Hines, Associate Professor at the NNF Center for Basic Metabolic Research at the University of Copenhagen.
The comprehensive research project involved scientific contributions from more than 20 institutions worldwide. It was led by the NNF Center for Basic Metabolic Research at the University of Copenhagen, working in close collaboration with the Center for Adipocyte Signaling at the University of Southern Denmark.
Financial support for the investigation was provided by the Novo Nordisk Foundation, the European Research Council, the Lundbeck Foundation, the U.S. National Institutes of Health, and several additional funding organizations.
